Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.
Saved in:
| Title: | Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. |
|---|---|
| Authors: | Chekol Abebe E; Department of Biochemistry, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia., Yibeltal Shiferaw M; Department of Medicine, College of Health Science, Debre Tabor University, Debre Tabor, Ethiopia., Tadele Admasu F; Department of Biochemistry, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia., Asmamaw Dejenie T; Department of Biochemistry, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. |
| Source: | Frontiers in immunology [Front Immunol] 2022 Sep 02; Vol. 13, pp. 991092. Date of Electronic Publication: 2022 Sep 02 (Print Publication: 2022). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2022.991092 |
